ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of HO/03/03 10-40 Micro Grams to Treat Hard to Heal Wounds (H2H)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01772303
Recruitment Status : Unknown
Verified April 2013 by HealOr.
Recruitment status was:  Recruiting
First Posted : January 21, 2013
Last Update Posted : April 4, 2013
Sponsor:
Information provided by (Responsible Party):
HealOr

Brief Summary:
This multicenter, prospective, open-label, outpatient study will assess the safety and efficacy of HO/03/03 10µg applied topically once daily for up to 24 weeks in up to 100 subjects with Hard to Heal documented chronic wounds of various etiologies (pressure ulcers, diabetic ulcers, post operational wounds surgical incisions ulcers of rheumatoid arthritis and trauma wounds) of at least 4 weeks documentation.

Condition or disease Intervention/treatment Phase
Hard to Heal Wounds Drug: HO/03/03 10-40 µg Early Phase 1

Detailed Description:
All subjects with a wound size of up to 56.25 cm2 (inclusive) will be administered 1 vial of 10 ml HO/03/03 10μg per administration. For each increase in wound size of up to 56.25 cm2 an additional vial of HO/03/03 10 μg will be added up to a maximal wound size area of 225 cm2 (will be measured by HealOr central reviewer) utilizing 40µg (4 vials) per administration. 15 min post treatment wounds will be dressed according to standard of care.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Prospective, Multicenter Study to Assess the Safety and Efficacy of HO/03/03 10-40 Micro Gram (Wound Size Dependence) Applied Topically for up to 24 Weeks in Subjects With Various Etiologies of Hard-to-Heal Wounds
Study Start Date : January 2013
Estimated Primary Completion Date : August 2013
Estimated Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: HO/03/03 10-40 micro gram
Topically treatment with HO/03/03 10-40µg once daily for up to 24 weeks. Subjects will receive treatment with HO/03/03 10µg at a dose of 1-4 vials (i.e. 10-40 µg/administration) daily depending on their wound size.
Drug: HO/03/03 10-40 µg
HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.



Primary Outcome Measures :
  1. Time to Heal [ Time Frame: up to 24 weeks ]
    1. 75% wound closure by or on study week 24 (Time to Event Analysis of incidence and time to 75% wound closure).


Secondary Outcome Measures :
  1. Wound closure [ Time Frame: up to 24 weeks ]
    1. Complete wound closure by or on week 24 (Time to Event Analysis of incidence and time to 100% wound closure).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years old and above.
  • Chronic wounds that have < 30% change in area from Screening
  • Have single / multiple wounds;
  • Have a Hard-to-Heal wound(s) of various etiologies

Exclusion Criteria:

  • Have a documented medical history of a significant cardiac, pulmonary, gastrointestinal, endocrine (other than Diabetes Mellitus type 1 or 2), hepatic or per the physician's discretion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01772303


Contacts
Contact: Yair Alegranti +972-54-3161581 yair@healor.com
Contact: Kira Olshvang +972-54-3161572 kira@healor.com

Locations
Israel
Maccabi Health Services, Wound Clinic Recruiting
Haifa, Israel
Contact: Michal Raba    +972-50-2400362    raba_m@mac.org.il   
Contact: Hanna Kaufman, MD    +972-50-9063142    dr.kaufmanh1@gmail.com   
Principal Investigator: Hanna Kaufman, MD         
Sponsors and Collaborators
HealOr

Responsible Party: HealOr
ClinicalTrials.gov Identifier: NCT01772303     History of Changes
Other Study ID Numbers: HO-H2H-01-2011
First Posted: January 21, 2013    Key Record Dates
Last Update Posted: April 4, 2013
Last Verified: April 2013

Keywords provided by HealOr:
Pressure Ulcers, diabetic Ulcers, post operational wounds

Additional relevant MeSH terms:
Wounds and Injuries